Compare ProShares Ultra QQQ ETF (QLD) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Repligen Corporation Common Stock — how do they compare? ProShares Ultra QQQ ETF trades at $90.32 (market cap $15.24B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: ProShares Ultra QQQ ETF is the larger of the two by market cap, and ProShares Ultra QQQ ETF is more actively traded (2,898,706 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra QQQ ETF for 36 Days and Repligen Corporation Common Stock for 0 Days on average.
| QLD | RGEN | |
|---|---|---|
Market Cap | $15.24B | $11.14B |
Volume | 2,898,706 | 1,259,263 |
Sector | Leveraged / Inverse | Health |
52-Week High | $100.77 | $194.57 |
52-Week Low | $57.16 | $102.87 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD (ProShares Ultra QQQ ETF) trades at $96.42, down 0.68% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF provides 2x leveraged exposure to the Nasdaq-100 index, positioning it as a less volatile alternative to triple-leveraged products during market downturns. Recent institutional buying by 180 Wealth Advisors LLC increased their position by 29.4% in Q2 2026, signaling confidence in the fund's strategy.
The outlook for QLD remains tied to Nasdaq-100 performance, with technical support at $95-$97 and resistance at $98-$99. While leveraged ETFs offer amplified returns, they carry elevated risk from daily rebalancing and market volatility. Investors should monitor Fed policy impacts and tech sector momentum for directional cues, with the current setup favoring tactical positions above key support levels.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
